Literature DB >> 2867187

Antagonism of 5-methoxy-N,N-dimethyltryptamine-induced changes in postdecapitation convulsions in rats by repeated treatment with drugs enhancing 5-hydroxytryptamine neurotransmission.

T Archer, B Tandberg, L Rènyi, S B Ross.   

Abstract

Repeated administration of drugs that increase tryptaminergic neurotransmission antagonized the increase in latency to onset and the duration of postdecapitation convulsions (PDCs) induced by an acute 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) injection; Zimelidine (2 X 5 mg kg-1), fluoxetine (2 X 5 mg kg-1), amiflamine (2 X 2.5 mg kg-1) and alpha-ethyltryptamine (2 X 2.5 mg kg-1) administered orally over 10 days caused a substantial blockade of the increase in latency to onset and duration of PDCs following 5-MeODMT, whereas alaproclate (2 X 5 mg kg-1), clorgyline (1 X 1 mg kg-1) and pargyline (2 X 2.5 mg kg-1) caused a lesser blockade. Repeated 5-MeODMT (3 X 2 mg kg-1) administration blocked the acute effects of 5-MeODMT (2 and 4 mg kg-1) upon PDCs completely. These findings indicate down-regulation of the 5-hydroxytryptamine receptors which mediate the action of 5-MeODMT on the PDCs and offer a simple model system for studying 5-HT receptor sensitivity changes at the spinal level.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2867187     DOI: 10.1111/j.2042-7158.1985.tb05103.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  2 in total

1.  Noradrenaline-stimulated inositol phospholipid breakdown as a measure of alpha 1-adrenoceptor function in rat hippocampal miniprisms after repeated antidepressant treatment.

Authors:  C J Fowler; W Danysz; T Archer
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

2.  The inhibition of the cage-leaving response--a model for studies of the serotonergic neurotransmission in the rat.

Authors:  L Rényi; T Archer; B G Minor; B Tandberg; A Fredriksson; S B Ross
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.